JMP reiterates Cytogen at market outperform

Cytogen Corp. was reiterated at market outperform by JMP Securities analyst Charles C. Duncan. The company's fourth-quarter 2005 results show solid product sales, and JMP expects potential commercial expansion for 2006. Revenues in the fourth quarter of $4.2 million were driven by Quadramet and ProstaScint sales of $2.2 million and $2.1 million. Net loss of $8.4 million, or $0.25 per share, was lower than consensus of a $0.44 loss and JMP estimates of a $0.47 loss. Shares of the Princeton, N.J., biopharmaceutical company were up 1 cent, or 0.34%, at $2.92 on volume of 110,861 shares versus the three-month running average of 196,294 shares. (Nasdaq: CYTO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.